Wesbanco Bank Inc. Trims Stock Position in Johnson & Johnson $JNJ

Wesbanco Bank Inc. lessened its holdings in Johnson & Johnson (NYSE:JNJ) by 1.9% during the 4th quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 146,806 shares of the company’s stock after selling 2,815 shares during the period. Johnson & Johnson accounts for approximately 0.8% of Wesbanco Bank Inc.’s portfolio, making the stock its 23rd largest holding. Wesbanco Bank Inc.’s holdings in Johnson & Johnson were worth $30,382,000 as of its most recent SEC filing.

Several other institutional investors and hedge funds also recently modified their holdings of the business. Chesapeake Wealth Management lifted its holdings in shares of Johnson & Johnson by 4.9% in the fourth quarter. Chesapeake Wealth Management now owns 8,078 shares of the company’s stock valued at $1,672,000 after purchasing an additional 374 shares in the last quarter. Strategic Wealth Advisors LLC purchased a new stake in shares of Johnson & Johnson in the fourth quarter valued at about $106,000. Anfield Capital Management LLC lifted its holdings in shares of Johnson & Johnson by 40.1% in the fourth quarter. Anfield Capital Management LLC now owns 206 shares of the company’s stock valued at $43,000 after purchasing an additional 59 shares in the last quarter. International Assets Investment Management LLC lifted its holdings in shares of Johnson & Johnson by 7.1% in the fourth quarter. International Assets Investment Management LLC now owns 17,837 shares of the company’s stock valued at $3,691,000 after purchasing an additional 1,183 shares in the last quarter. Finally, Coston McIsaac & Partners lifted its holdings in shares of Johnson & Johnson by 1.7% in the fourth quarter. Coston McIsaac & Partners now owns 39,022 shares of the company’s stock valued at $8,075,000 after purchasing an additional 663 shares in the last quarter. Hedge funds and other institutional investors own 69.55% of the company’s stock.

Johnson & Johnson Stock Performance

Shares of JNJ stock opened at $221.17 on Friday. Johnson & Johnson has a one year low of $146.12 and a one year high of $251.71. The company has a debt-to-equity ratio of 0.46, a quick ratio of 0.77 and a current ratio of 1.03. The company has a 50 day moving average price of $237.59 and a 200 day moving average price of $220.58. The firm has a market capitalization of $532.41 billion, a price-to-earnings ratio of 25.57, a price-to-earnings-growth ratio of 2.17 and a beta of 0.27.

Johnson & Johnson (NYSE:JNJ) last released its quarterly earnings data on Tuesday, April 14th. The company reported $2.70 earnings per share (EPS) for the quarter, topping the consensus estimate of $2.68 by $0.02. Johnson & Johnson had a net margin of 21.83% and a return on equity of 32.60%. The company had revenue of $24.06 billion during the quarter, compared to the consensus estimate of $23.60 billion. During the same period in the previous year, the firm earned $2.77 earnings per share. Johnson & Johnson’s revenue for the quarter was up 9.9% on a year-over-year basis. Johnson & Johnson has set its FY 2026 guidance at 11.450-11.650 EPS. Sell-side analysts anticipate that Johnson & Johnson will post 11.57 EPS for the current year.

Johnson & Johnson Increases Dividend

The firm also recently disclosed a quarterly dividend, which will be paid on Tuesday, June 9th. Shareholders of record on Tuesday, May 26th will be paid a dividend of $1.34 per share. This is an increase from Johnson & Johnson’s previous quarterly dividend of $1.30. This represents a $5.36 annualized dividend and a yield of 2.4%. The ex-dividend date is Tuesday, May 26th. Johnson & Johnson’s payout ratio is presently 61.97%.

Insider Activity at Johnson & Johnson

In other Johnson & Johnson news, EVP Timothy Schmid sold 1,322 shares of the business’s stock in a transaction that occurred on Friday, February 20th. The shares were sold at an average price of $245.66, for a total transaction of $324,762.52. Following the completion of the sale, the executive vice president directly owned 25,447 shares in the company, valued at $6,251,310.02. The trade was a 4.94% decrease in their ownership of the stock. The transaction was disclosed in a filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, EVP Vanessa Broadhurst sold 6,197 shares of the business’s stock in a transaction that occurred on Tuesday, February 17th. The stock was sold at an average price of $243.39, for a total transaction of $1,508,287.83. Following the sale, the executive vice president owned 23,003 shares of the company’s stock, valued at approximately $5,598,700.17. This represents a 21.22% decrease in their ownership of the stock. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 30,142 shares of company stock valued at $7,360,528. 0.16% of the stock is owned by insiders.

Key Headlines Impacting Johnson & Johnson

Here are the key news stories impacting Johnson & Johnson this week:

• Positive Sentiment: Erste Group Bank raised its FY2027 earnings estimate for Johnson & Johnson to $12.66 per share from $12.63, reinforcing the view that earnings power remains solid and slightly better than expected.
• Positive Sentiment: J&J’s cancer business continues to be a growth driver, with reports highlighting Darzalex, Erleada, and newer launches helping oncology sales grow strongly in the latest quarter and supporting the company’s long-term target of $50 billion in cancer sales by 2030. Darzalex, Erleada & New Drugs Keep J&J’s Oncology Engine Charged in Q1
• Positive Sentiment: Several articles also pointed to Johnson & Johnson as a favored dividend compounder, which can appeal to income investors looking for stability and long-term payouts. This Dividend Pro Likes Banks, Semi-Equipment Stocks, Altria, and J&J
• Neutral Sentiment: J&J also launched its “Generation Fine” mental health campaign, which is more of a brand and awareness initiative than a direct earnings catalyst, though it underscores continued investment in neuropsychiatry. Johnson & Johnson launches Generation Fine
• Neutral Sentiment: At the same time, recent pipeline commentary was mixed: J&J reported positive progress in some programs, but one mid-stage inflammatory bowel disease candidate did not meet its main endpoint, creating some offsetting uncertainty. Johnson And Johnson Balances Mental Health Push With Mixed Pipeline Outlook

Analyst Upgrades and Downgrades

A number of equities analysts have recently weighed in on the stock. Guggenheim boosted their price objective on shares of Johnson & Johnson from $244.00 to $266.00 and gave the company a “buy” rating in a research report on Monday, April 20th. Morgan Stanley set a $283.00 price objective on shares of Johnson & Johnson in a research report on Wednesday, April 15th. The Goldman Sachs Group boosted their price objective on shares of Johnson & Johnson from $265.00 to $275.00 and gave the company a “buy” rating in a research report on Wednesday, April 15th. Scotiabank reissued an “outperform” rating on shares of Johnson & Johnson in a research report on Thursday, January 22nd. Finally, HSBC boosted their price objective on shares of Johnson & Johnson from $265.00 to $280.00 and gave the company a “buy” rating in a research report on Tuesday, March 17th. Eighteen analysts have rated the stock with a Buy rating and nine have issued a Hold rating to the company. According to MarketBeat, the company presently has a consensus rating of “Moderate Buy” and a consensus target price of $252.48.

Johnson & Johnson Profile

Johnson & Johnson is a multinational healthcare company headquartered in New Brunswick, New Jersey, that develops, manufactures and markets a broad range of products across pharmaceuticals, medical devices and previously consumer health. Founded in 1886 by the Johnson family, the company has grown into a global healthcare organization with operations and sales in many countries around the world.

The company’s pharmaceuticals business, organized largely under its Janssen research and development organization, focuses on prescription medicines across therapeutic areas such as immunology, infectious disease, oncology and neuroscience.